Over the past decade, we have amassed linked molecular and therapeutic treatment data from hundreds of thousands of patients, forming a vast data library within the CODEai database to support precision medicine research and development. We innovate novel, proprietary analyses at the forefront of biomarker discovery and molecularly informed drug development using the quality and breadth of real-world treatment and response data. Caris then further translates these innovations into practice through prospectively testing and enabling enrollment into clinical research programs across our vast network.
Caris CODEai-informed drug development supporting solutions are designed specifically to help our partners build precision medicines. Our comprehensive approach to drug development partnering is designed to create real-world data informed study protocols, identify and accelerate access to clinical trials, lower drug development costs and provide regulatory support with access to Caris’ platform WTS RNA, and WES DNA Companion Diagnostic programs.
Designed to maximize the chances of success for clinical trials and address many patient accrual challenges facing biopharma partners in the world of precision medicine.
Our data-driven, molecular insights are changing the landscape of precision medicine with actionable insights from retrospective, epidemiologic, and real-time molecular data to enhance research and commercial activities.
At our 66,000 square foot, state-of-the-art laboratory located in Phoenix, Arizona, we provide high quality, reliable molecular testing services for all stages of the drug development cycle and routine clinical use.
Caris CODEaiTM is a cutting edge data service providing access to real-world integrated molecular and clinical outcomes data. CODEai integrates an extensive database of Caris profiled patient cases with 200,000+ associated outcomes, one of the largest combined datasets in the world.
Allows for cohort analysis based on:
Unlike other tumor profiling services on the market, we use the best available technologies for biomarker identification. This approach allows our medical teams to more fully understand the biology of the tumor, which helps our oncologist colleagues plan their treatment strategy.
Caris CODEai data services augment drug target discovery to integrate molecular profiling data and clinical outcomes. The CODEai portal provides access to 200,000+ matched patient datasets with linked EMR, prescriptions and outcomes. CODEai contains one of the largest comprehensive molecular profiling linked datasets in the world and can accelerate your target discovery.
Caris Life Sciences also uses a variety of technology platforms to conduct pre-clinical research with biopharma partners, including Next Generation Sequencing and Mass Spectrometry.
ADAPT Biotargeting System™ is a proprietary platform using enriched molecular libraries called ADAPTamers™ to identify and bind to biological targets of interest. This platform has the ability to reveal novel biomarkers and drug targets, derive molecular mechanisms of action and, among others, assess therapeutic sensitivity and resistance. It is currently being utilized in advanced diagnostics and drug development programs across multiple diseases.
Discover important biological information utilizing a variety of sample types:
We're pushing the boundaries of precision medicine
Connecting patients with the most up-to-date and relevant clinical trials